New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
04:55 EDTDHR, DHR, DHR, TEVA, TEVA, TEVA, GMED, GMED, GMED, RHHBY, RHHBY, RHHBY, MDCO, MDCO, MDCO, NVO, NVO, NVO, GILD, GILD, GILD, OMI, OMI, OMI, PKI, PKI, PKI, WCG, WCG, WCG, BDX, BDX, BDXGoldman to hold a conference
35th Annual Global Healthcare Conference to be held in Rancho Palos Verdes, California on June 10-12.
News For DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
February 18, 2015
08:21 EDTWCGWellCare price target raised to $105 from $95 at Leerink
Subscribe for More Information
07:45 EDTTEVAEagle Pharmaceuticals price target raised to $37 from $30 at Cantor
Subscribe for More Information
07:29 EDTWCGWellCare management team has improved, says Stifel
Subscribe for More Information
07:13 EDTTEVAEagle Pharmaceuticals target raised to $43 from $25 at William Blair
William Blair raised its price target for Eagle Pharmaceuticals (EGRX) to $43 saying the company's agreement with Teva (TEVA) removes a major overhang on the stock. William Blair says the deal is a significant positive for Eagle since it removes litigation risk and moves the company immediately into profitability. It keeps an Outperform rating on the stock.
07:01 EDTMDCOThe Medicines Co. reports Q4 adjusted EPS 20c, consensus (82c)
Subscribe for More Information
06:56 EDTWCGObamacare enrollment exceeded goal, Politico reports
Subscribe for More Information
February 17, 2015
17:36 EDTOMIOwens & Minor increases dividend 1% to 25.25c
Subscribe for More Information
17:36 EDTOMIOwens & Minor initiates search for successor to CEO
Owens & Minor announced that its board of directors is initiating a search to identify a successor to President & CEO James L. Bierman. During the board’s regular succession planning process, Bierman, 62, informed the board of his own horizon for retirement and asked that a search for his successor be initiated. Bierman will continue to serve in his current role until his successor is named, and he indicated to the board that he will be fully available to assist in the transition.
17:35 EDTOMIOwens & Minor sees FY15 adjusted EPS $1.90-$1.95, consensus $1.95
Subscribe for More Information
17:34 EDTOMIOwens & Minor reports Q4 adjusted EPS 49c, consensus 50c
Subscribe for More Information
17:13 EDTGILDPoint72 gives quarterly update on stakes
Subscribe for More Information
16:00 EDTGILDOptions Update; February 17, 2015
Subscribe for More Information
15:32 EDTOMINotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Devon Energy (DVN), consensus $1.05... Vornado Realty (VNO), consensus $1.23... Analog Devices (ADI), consensus 61c... FirstEnergy (FE), consensus 75c... CF Industries (CF), consensus $5.08... Agilent Technologies (A), consensus 41c... Cimarex Energy (XEC), consensus 82c... Flowserve (FLS), consensus $1.13... Fossil (FOSL), consensus $3.07... Rackspace (RAX), consensus 19c... Norwegian Cruise Line (NCLH), consensus 37c... Jack in the Box (JACK), consensus 87c... Cloud Peak Energy (CLD), consensus 7c... La-Z-Boy (LZB), consensus 38c... KAR Auction Services (KAR), consensus 29c... Owens & Minor (OMI), consensus 50c... Valmont Industries (VMI), consensus $1.65... Realty Income (O), consensus 66c.
15:15 EDTBDXBecton Dickinson management to meet with William Blair
Subscribe for More Information
13:18 EDTGILDOmega Advisors gives quarterly update on stakes
Subscribe for More Information
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
08:47 EDTTEVABioTime provides update on Cell Cure's product development, partnering
BioTime (BTX) and its subsidiary Cell Cure Neurosciences provided an update on Cell Cure’s product development and partnering activities. On February 16, Cell Cure opened the clinical trial of OpRegen titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy” at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial cells with high purity and potency. On October 31, 2014, the FDA cleared Cell Cure's Investigational New Drug application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration with geographic atrophy.The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. Cell Cure also announced that the option granted to Teva (TEVA) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product. Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells is expected to issue on February 17. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
08:39 EDTTEVATeva deal small but important, says BMO Capital
Subscribe for More Information
08:35 EDTTEVATeva announces launch of generic Lovenox and Zyvox in U.S.
Subscribe for More Information
07:04 EDTTEVATeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use